Clinical trials
Phase 1/2 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
| Completed | 5 |
| Terminated | 5 |
| Active, not recruiting | 4 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 3 |
| Novartis Pharmaceuticals | 3 |
| Princess Maxima Center for Pediatric Oncology | 3 |
| Celgene | 2 |
| AbbVie | 1 |
| Amgen | 1 |
| Amgen Research (Munich) GmbH | 1 |
| Bristol-Myers Squibb | 1 |
| ERYtech Pharma | 1 |
| Hoffmann-La Roche | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 23 |
| Leukemia | 9 |
| Leukemia, Myeloid, Acute | 8 |
| Recurrence | 8 |
| Burkitt Lymphoma | 4 |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia, Biphenotypic, Acute | 2 |
| Lymphatic Diseases | 2 |
| Lymphoma | 2 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.